Antitumor Activity and Safety of Trastuzumab Deruxtecan in Patients With HER2-Low–Expressing Advanced Breast Cancer: Results From a Phase Ib Study
2020 · Journal of Clinical Oncology · 797 citations
https://doi.org/10.1200/jco.19.02318
S
Shunji Takahashi
Claim or correct this author profile
Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.
615
Papers
15.4K
Citations
54
h-index
220
i10-index
Shunji Takahashi is an academic researcher from Japanese Foundation For Cancer Research. The author has contributed to research in topics: HER2/EGFR in Cancer Research & Lung Cancer Treatments and Mutations & Head and Neck Cancer Studies. The author has an h-index of 54, co-authored 523 publications.
ORCID: 0000-0002-5031-1953Papers by this author
worksAntiresorptive agent-related osteonecrosis of the jaw: Position Paper 2017 of the Japanese Allied Committee on Osteonecrosis of the Jaw
2016 · Journal of Bone and Mineral Metabolism · 295 citations
https://doi.org/10.1007/s00774-016-0810-7
Trastuzumab deruxtecan (DS-8201a) in patients with advanced HER2-positive gastric cancer: a dose-expansion, phase 1 study
2019 · The Lancet Oncology · 227 citations
https://doi.org/10.1016/s1470-2045(19)30088-9
Pembrolizumab plus concurrent chemoradiotherapy versus placebo plus concurrent chemoradiotherapy in patients with locally advanced squamous cell carcinoma of the head and neck (KEYNOTE-412): a randomised, double-blind, phase 3 trial
2024 · The Lancet Oncology · 181 citations
https://doi.org/10.1016/s1470-2045(24)00100-1
Patritumab Deruxtecan (HER3-DXd), a Human Epidermal Growth Factor Receptor 3–Directed Antibody-Drug Conjugate, in Patients With Previously Treated Human Epidermal Growth Factor Receptor 3–Expressing Metastatic Breast Cancer: A Multicenter, Phase I/II Trial
2023 · Journal of Clinical Oncology · 111 citations
https://doi.org/10.1200/jco.23.00882
Tucatinib and Trastuzumab for Previously Treated Human Epidermal Growth Factor Receptor 2–Positive Metastatic Biliary Tract Cancer (SGNTUC-019): A Phase II Basket Study
2023 · Journal of Clinical Oncology · 93 citations
https://doi.org/10.1200/jco.23.00606
Research topics
topicsChat about Author
Papers
Chat
Click to start Chat